Vorapaxar is a newer antiplatelet drug that targets which specific receptor?
Show answer and explanation
Correct answer: Protease-activated receptor-1 (PAR-1)
Vorapaxar is a competitive antagonist of PAR-1, the primary receptor for thrombin on human platelets. By blocking this pathway, it inhibits thrombin-induced platelet aggregation without affecting thrombin's ability to cleave fibrinogen.
Keep practicing
More Antiplatelet Drugs questions
- Which side effect is uniquely associated with Ticagrelor therapy and may lead to drug discontinuation?
- What is the rationale for using 'Dual Antiplatelet Therapy' (DAPT) in patients following coronary stent placement?
- Which of the following agents is a synthetic heptapeptide that reversibly inhibits the Glycoprotein IIb/IIIa receptor?
- How long before an elective surgery should Aspirin typically be discontinued to allow for the restoration of normal platelet function?
- Cilostazol is primarily indicated for the treatment of which condition?
- Which antiplatelet drug can cause a rare but serious side effect known as Thrombotic Thrombocytopenic Purpura (TTP)?